REFERENCES:
1. Bergman, H., & Deuschl, G. (2002); “Pathophysiology of parkinsion’s disease: From clinical neurology to basic neuroscience and back”; Movement Disorders; 17(SUPPL. 3); 28-40.
2. Canet R., Geoffrey P. Lomax, Ellen G. Feigal, Catherine Priest (2014); “Proceedings: Cell Therapies for Parkinson’s disease From Discovery to Clinic”; California Institute for Regenerative Medicine, San Francisco, California, USA 2014.
3. Chen L, Feany M.B.(2005); “Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease”; Nat Neurosci; 8(5); 657-663.
4. Choi, S. S., Ryu, G. H., Kim, D. H., Lee, D. S., Lee, S., Kim, S. Y., J Lee, H. (2017); “Stem Cell Applications in Parkinson’s Disease”; Journal of Alzheimer’s Disease & Parkinsonism; 7(1); 1-3.
5. Cooper, O., Seo, H., Andrabi, S. et al. (2012); “Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease”; SciTranslMed; 4(141); 141ra90
6. Correia, A. S., Anisimov, S. V., Li, J. Y., & Brundin, P. (2005); “Stem cell-based therapy for Parkinson’s disease”, Annals of Medicine; 37(7); 487-498.
7. de la Fuente-Fernandez , R., Schulzer M, Mak E et al.( 1998); “The role of the Lewy body in idiopathic Parkinsonism”; Parkinsonism Related Disorder; 4(2); 73-77.
8. Dexter, D.T., Wells, F.R., Lees, A.J., et al. (1989); “Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease”; Journal of Neurochemistry; 52(6); 1830-1836.
9. Fehmida Farid Khan (2013); “Parkinson disease and use of stem cells for therapeutic approaches of Parkinson disease”; IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS); 7(5); 73–82.
10. Fu MH., Li CL., Lin HL, Chen, PC., Calkins M J., Chang YF., Yang SH (2015); “Stem cell transplantation therapy in Parkinson’s disease”; Springer Plus; 4(1); 597.
11. Kalra K, Tomar PC (2014), “Stem Cell: Basics, Classification and Application”; American Journal of Phytomedicine and Clinical Therapeutics; 2(7); 919-930
12. Kim, J.-H., Auerbach, J. M., Rodríguez-Gómez, J. A., Velasco, I., Gavin, D., Lumelsky, N., McKay, R. (2002); “Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease”, Nature; 418(6893); 50-56.
13. Lindvall, O., & Kokaia, Z. (2006); “Stem cells for the treatment of neurological disorders”; Nature; 441(7097), 1094-1096
14. Nguyen, H.N., Byers, B., Cord, B., et al. (2011); “LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress”; Cell Stem Cell; 8(3); 267-280.
15. Rana AQ. (2011); “Etiology and pathophysiology of Parkinson’s disease”; Intech open, UK
16. Rusu E., Necula, L. G., Neagu, A. I., Alecu, M., Stan, C., Albulescu, R., & Tanase, C. P. (2016); “Current status of stem cell therapy: Opportunities and limitations”; Turkish Journal of Biology; 40(5); 955-967.
17. Shulman JM, De Jager PL, Feany MB (2011); “Parkinson’s disease: Genetics and pathogenesis”; Annu Rev Pathol,; 6; 193-222.
18. Standaert D.G , Saint-Hilaire M.H, Thomas C. (2006); “Parkinson’s Disease Handbook”, American Parkinson’s Disease Association, NY.
19. Su P., Loane C & Politis M (2011), “The Use of Stem Cells in the Treatment of Parkinsons Disease”; Insciences Journal; 1(3); 136-156
20. Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR (2016); “Visual dysfunction in Parkinson’s disease”; Brain- A Journal of Neurology; 139(11); 2827-2843.
Recent Topics